FDA approves new higher-dose version of Wegovy shots

Federal regulators have approved a higher-dose version of Wegovy, the popular obesity treatment, potentially offering patients a more effective option for weight management.

On Thursday, the U.S. Food and Drug Administration granted approval for a 7.2-milligram dose of semaglutide, the active ingredient in Wegovy, manufactured by Danish pharmaceutical company Novo Nordisk. This new formulation triples the previously approved maximum dosage of 2.4 milligrams, which is administered as a weekly injection.

The FDA expedited the review through its ultra-fast drug review program, with approval granted just 54 days after the review request was accepted. According to Novo Nordisk, the new higher-dose version, called Wegovy HD, will be available in U.S. pharmacies starting in April. The company has yet to announce pricing details.

European regulators had already approved the higher-dose version in February, indicating growing global acceptance of more potent weight management medications.

Clinical trials demonstrated that Wegovy HD produced significantly better results than the standard dose. Study participants using the 7.2-milligram version lost approximately 19% of their body weight (nearly 47 pounds) over almost 17 months, compared to 16% (about 39 pounds) with the 2.4-milligram dose. These findings were published in the medical journal Lancet Diabetes & Endocrinology.

The development of the higher dose was driven by the recognition that some patients weren’t achieving their weight-loss goals with the standard formulation. This highlights the pharmaceutical industry’s growing focus on customized approaches to obesity treatment, which affects more than 40% of American adults.

Dr. Jody Dushay, an endocrinologist and obesity expert at Harvard Medical School, expressed support for the approval, noting that it “may be especially helpful for people” who tolerate the lower dose well but experience “suboptimal weight loss.” She added that it could also benefit patients who don’t respond adequately to Eli Lilly’s competing obesity drug Zepbound.

However, the increased potency comes with heightened side effects. More than 70% of patients taking the higher dose reported gastrointestinal issues like nausea, vomiting, and constipation, compared to over 60% on the standard dose and about 43% on placebo.

A particularly notable side effect was dysesthesia—unpleasant skin sensations including burning, stabbing, or electric shock-like feelings—which affected approximately 23% of those on the higher dose, versus 6% on the standard dose and less than 1% on placebo.

Serious adverse events occurred in nearly 7% of patients taking the 7.2-milligram dose, compared to about 11% on the 2.4-milligram dose and about 5% on placebo. Dr. Dushay characterized the dosage increase as “quite a big jump,” particularly without intermediate options, and emphasized the importance of monitoring real-world side effects outside the controlled environment of clinical trials.

This approval comes amid explosive growth in the GLP-1 receptor agonist market, which includes Wegovy and Eli Lilly’s Zepbound (tirzepatide). These medications have transformed obesity treatment by offering non-surgical options for significant weight loss, though persistent supply shortages have limited access.

In December, the FDA also approved an oral version of Wegovy containing 25 milligrams of semaglutide, the higher amount necessary for effective absorption through the digestive system. This pill formulation offers an alternative for patients who prefer not to use injections.

The obesity treatment landscape continues to evolve rapidly, with pharmaceutical companies racing to develop more potent, convenient options for a condition long considered difficult to treat effectively. Analysts project the global obesity drug market could reach $100 billion annually by 2030, underscoring both the medical need and commercial opportunity these treatments represent.